| Trial ID: | L6168 |
| Source ID: | NCT03426085
|
| Associated Drug: |
Liraglutide 6 Mg Solution For Injection
|
| Title: |
The Effects of Liraglutide on Sudomotor Function and Inflammation in Type 2 Diabetes
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Autonomic Nervous System Diseases|Sweat Gland Diseases|Diabetic Neuropathy With Neurologic Complication
|
| Interventions: |
DRUG: Liraglutide 6 mg Solution for Injection|OTHER: Placebo
|
| Outcome Measures: |
Primary: Sudomotor Function, Changes in peripheral autonomic function using sudorimetry (Sudoscan) after 1 year of treatment., One Year | Secondary: Inflammatory Markers C-Reactive Protein (CRP), Changes on markers of inflammation and oxidative/nitrosative stress including C-reactive protein (CRP), One year|Inflammatory Markers IL-1β, Changes on markers of inflammation and oxidative/nitrosative stress including IL-1β, One Year|Inflammatory Markers IL6, Changes on markers of inflammation and oxidative/nitrosative stress including IL6, One Year|Inflammatory Markers Tumor Necrosis factor α (TNF α), Changes on markers of inflammation and oxidative/nitrosative stress including Tumor Necrosis factor α (TNF α), One Year
|
| Sponsor/Collaborators: |
Sponsor: Eastern Virginia Medical School
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
44
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: TRIPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR)|Primary Purpose: PREVENTION
|
| Start Date: |
2016-05
|
| Completion Date: |
2020-08
|
| Results First Posted: |
|
| Last Update Posted: |
2019-02-11
|
| Locations: |
Strelitz Diabetes Center, Norfolk, Virginia, 23510, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT03426085
|
